Field
Medicine
Horizon
σ Sigma · 2029–2035
Lead center
Living Systems
Maturity
Developing — prototypes scaling toward deployment
Why it matters
It can deliver drugs precisely to diseased tissue, cross biological barriers, and detect disease earlier, reducing side effects and enabling new therapies.
Where it stands
Nanoparticle drugs and mRNA-lipid systems are in clinical use; more sophisticated targeting and nanoscale devices are in research.
How ASIZ approaches it
The discovery loop, applied.
Through the Living Systems center, ASIZ aims the discovery loop at nanomedicine: frontier models survey the literature and simulate the possibilities, rank the experiments most likely to resolve the open questions, and partner labs run the decisive ones — with results shared openly.